CVT 3634
Latest Information Update: 27 Apr 2007
Price :
$50 *
At a glance
- Originator CV Therapeutics
- Class Small molecules
- Mechanism of Action Adenosine A2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 27 Apr 2007 Discontinued - Preclinical for Vascular disorders in USA (unspecified route)
- 06 Jun 2001 Preclinical development for Vascular disorders in USA (unspecified route)